A New Supplement for the Immune Response to HPV Infection
Launched by UNIVERSITY OF MESSINA · Oct 7, 2014
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women with high risk HPV infection
- • histological diagnosis of L-SIL
- Exclusion Criteria:
- • women with no high risk HPV infection
- • women without histological diagnosis of L-SIL
About University Of Messina
The University of Messina, a prominent research institution located in Sicily, Italy, is dedicated to advancing medical science through innovative clinical trials. Renowned for its commitment to high-quality research and education, the university fosters interdisciplinary collaboration among its faculty and students to address pressing health challenges. With a focus on patient-centered approaches, the University of Messina aims to contribute valuable insights to the medical community, enhancing treatment options and improving health outcomes through rigorous clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials